TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26599376
Drug: Aspirin intake
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin intake at 8.00 PM
Study: 25611785
Drug: Corticosteroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid treatment in the GLUCOLD trial
Study: 16403243
Drug: Combined cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined cognitive behavioral therapy (CBT) and pharmacotherapy intervention
Study: 16403243
Drug: Usual primary-care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual primary-care treatment
Study: 12602908
Drug: DCT 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCT 50 mg/m2 bimonthly schedule
Study: 12602908
Drug: DCT 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCT 75 mg/m2 every 3 weeks (calibration arm)
Study: 12602908
Drug: DCT 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCT 60 mg/m2 bimonthly schedule
Study: 12602908
Drug: DCT 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCT 40 mg/m2 bimonthly schedule
Study: 12602908
Drug: DCT 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCT 75 mg/m2 every 3 weeks
Study: 9100679
Drug: Prophylactic antibiotics
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotics (three perioperative doses of cefazolin)
Study: 31679753
Drug: Psychological treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological treatments for depression
Study: 27273710
Drug: SFC50 (salmeterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: SFC50 (salmeterol xinafoate 50 μg/day and fluticasone propionate 100 μg/day)
Study: 20566010
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg tamsulosin oral tablets once daily (GB)
Study: 16481664
Drug: Methylphenidate transdermal
Normalized name: methylphenidate Transdermal System
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate transdermal system (MTS) 10, 16, 20, and 27 mg applied in the morning for 9 hours
Study: 9095512
Drug: Monoclonal antibodies
Normalized name: Monoclonal antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibodies in 'Other Blood Groups'
Study: 8250363
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg midazolam orally and 0.2 mg sublingual buprenorphine (group 2)
Study: 8250363
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg midazolam orally and 0.4 mg sublingual buprenorphine (group 3)
Study: 8250363
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg midazolam orally (group 1)
Study: 3879105
Drug: 24R,25 (OH)2D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24R,25 (OH)2D3 (10 micrograms daily)
Study: 31074641
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of physician's choice (control)
Study: 25538178
Drug: Vandetanib 300
Normalized name: vandetanib 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vandetanib 300 mg monotherapy (V)
Study: 25538178
Drug: Vandetanib 100
Normalized name: vandetanib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vandetanib 100 mg plus gemcitabine (V/G)
Study: 25538178
Drug: Gemcitabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine plus placebo (G/P)
Study: 23161001
Drug: Yohimbine 16.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine 16.2 mg
Study: 23161001
Drug: Yohimbine 32.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine 32.4 mg
Study: 48347
Drug: Hydromorphone 1
Normalized name: HYDROMORPHONE 1MG/ML NS INJ 50ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone 1 mg
Study: 19238452
Drug: Simvastatin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (5 mg for children ≤30 kg, 10 mg for children >30 kg, doubled for two additional months)
Study: 16918945
Drug: Glucocorticoid plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoid plus mineralocorticoid hormone replacement
Study: 10911825
Drug: Stinging nettle
Normalized name: Stinging Nettle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stinging nettle leaf (Urtica dioica) applied daily for one week
Study: 3535980
Drug: Applied relaxation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied relaxation training (ART) taught during one session using participant demonstration, written instructions, taped instructions, or a combination of all three; practice at home encouraged.
Study: 28295581
Drug: Prolonged-release tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-release tacrolimus (initial dose: 0.2 mg/kg/day)
Study: 28295581
Drug: Immediate-release tacrolimus
Normalized name: tacrolimus Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release tacrolimus (initial dose: 0.1 mg/kg/day)
Study: 23569311
Drug: Bevacizumab 15
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 15 mg/kg with docetaxel 100 mg/m(2) and trastuzumab 8 mg/kg loading dose followed by 6 mg/kg, administered every 3 weeks
Study: 23569311
Drug: Docetaxel 100
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 100 mg/m(2) and trastuzumab 8 mg/kg loading dose followed by 6 mg/kg without bevacizumab, administered every 3 weeks
Study: 23569311
Drug: Bevacizumab 15
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 15 mg/kg with docetaxel and trastuzumab
Study: 23569311
Drug: Bevacizumab-containing therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab-containing therapy
Study: 19500335
Drug: Infliximab (anti-TNF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (anti-TNF therapy)
Study: 14699862
Drug: L dose
Normalized name: Medrol Dosepak
Approvals — FDA: no, EMA: no, PMDA: no
Description: L dose group (8 mumol Fe/kg)
Study: 14699862
Drug: H dose
Normalized name: Qvar with Dose Counter
Approvals — FDA: no, EMA: no, PMDA: no
Description: H dose group (12 mumol Fe/kg)
Study: 8893144
Drug: Oral calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcitriol (0.25 microgram/day)
Study: 1709686
Drug: Chemotherapy followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy followed by pelvic radiotherapy (CT + RT; arm B) - three cycles of chemotherapy (BOMP: bleomycin, vincristine, mitomycin, and cisplatin) followed by RT
Study: 6402369
Drug: Oral MESNA
Normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral MESNA (840 mg/m2 at 0 hr, 4 hr, and 8 hr p.i.)
Study: 28535076
Drug: Cingal (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cingal (4 mL, 88 mg hyaluronic acid plus 18 mg triamcinolone hexacetonide)
Study: 28535076
Drug: Monovisc (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovisc (4 mL, 88 mg hyaluronic acid)
Study: 28535076
Drug: Saline (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (4 mL, 0.9%)
Study: 24804695
Drug: Testosterone therapy
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone therapy (intramuscular testosterone undecanoate for 40 weeks)
Study: 23122652
Drug: Alemtuzumab 12
Normalized name: alemtuzumab 12 MG in 1.2 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alemtuzumab 12 mg per day (IV)
Study: 23122652
Drug: Interferon beta
Normalized name: Interferon beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon beta 1a 44 μg (SC)
Study: 20573586
Drug: Oral Glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Glucose Tolerance Test (OGTT) in CP+NGT group
Study: 20573586
Drug: Intravenous Glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Glucose Tolerance Test (IVGTT) in CP+NGT group
Study: 20573586
Drug: Oral Glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Glucose Tolerance Test (OGTT) in CP+IGT group
Study: 20573586
Drug: Intravenous Glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Glucose Tolerance Test (IVGTT) in CP+IGT group
Study: 20573586
Drug: Oral Glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Glucose Tolerance Test (OGTT) in CP+DM group
Study: 20573586
Drug: Intravenous Glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Glucose Tolerance Test (IVGTT) in CP+DM group
Study: 20573586
Drug: Oral Glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Glucose Tolerance Test (OGTT) in healthy subjects
Study: 20573586
Drug: Intravenous Glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Glucose Tolerance Test (IVGTT) in healthy subjects
Study: 15625138
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg oral furosemide daily for 5 days with oral potassium supplementation
Study: 20881606
Drug: amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: amlodipine 5 mg/d
Study: 10492056
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with alpha1‐AGP levels over 0.9 mg/ml
Study: 10492056
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with alpha1‐AGP levels less than 0.7 mg/ml
Study: 8942423
Drug: Vitamins C
Normalized name: MULTIVITAMINS CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamins C and E (1 g ascorbic acid and 400 mg dl-alpha-tocopheryl acetate)
Study: 8942423
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (400 mg dl-alpha-tocopheryl acetate)
Study: 8942423
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (1 g ascorbic acid)
Study: 23118720
Drug: 30% FFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30% FFA suppositories
Study: 17878744
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of alprazolam orally
Study: 14716761
Drug: Capecitabine at
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine at 1250 mg/m² twice daily on Days 2-15 and irinotecan at 300 mg/m² on Day 1 (Arm A)
Study: 14716761
Drug: Capecitabine at
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine at 1250 mg/m² twice daily on Days 2-15 and irinotecan at 150 mg/m² on Days 1 and 8 (Arm B)
Study: 14716761
Drug: Lower doses
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower doses of capecitabine (1000 mg/m²) and irinotecan (Arm A: 240 mg/m²; Arm B: 120 mg/m²)
Study: 3514082
Drug: Piroxicam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam (20 mg daily, with option to reduce to 10 mg at week 4 or 8)
Study: 3514082
Drug: Naproxen (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (750 mg daily, with option to reduce to 500 mg at week 4 or 8)
Study: 3345774
Drug: Adenosine (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine (doses of 20, 30, 40, 50, 60, 80 and 100% of the maximum tolerable dose)
Study: 17071213
Drug: Group behavior
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group behavior therapy (BT)
Study: 17071213
Drug: Group supportive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group supportive therapy (ST)
Study: 11093990
Drug: Standard balanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard balanced outpatient anesthetic with ondansetron 4 mg (Group II)
Study: 9373420
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy and maintenance cognitive therapy
Study: 9373420
Drug: Antidepressants and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants and maintenance antidepressants
Study: 9373420
Drug: Antidepressants and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants and maintenance cognitive therapy
Study: 1616387
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition (C)
Study: 3987804
Drug: Enteric-coated pellets
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated pellets of erythromycin base administered 1 hour before breakfast
Study: 2119396
Drug: Enteric-coated tablets
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated tablets
Study: 27759625
Drug: Gemifloxacin (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemifloxacin (320 mg single dose) plus amoxicillin (1g twice daily), bismuth (240 mg), and omeprazole (20 mg) for 14 days
Study: 27759625
Drug: Gemifloxacin-containing therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemifloxacin-containing therapy
Study: 21949432
Drug: Daily low‐pressure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily low‐pressure pulsatile lavage treatment with 1 L of normal saline at 11 psi of pressure
Study: 20470671
Drug: Gefitinib 250
Normalized name: gefitinib 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib 250 mg in combination with concurrent radiotherapy (RT) +/‐ concomitant cisplatin
Study: 20470671
Drug: Gefitinib and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib and RT with concurrent cisplatin
Study: 15998268
Drug: Ultrasonic re-treatment
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasonic re-treatment
Study: 15998268
Drug: Hand instrumentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hand instrumentation re-treatment
Study: 12921607
Drug: Ordinary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ordinary treatment of chronic gastritis (plan A)
Study: 12921607
Drug: Functional dyspepsia
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional dyspepsia treatment (plan B)
Study: 9010701
Drug: Morphine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (20 or 30 mg)
Study: 9010701
Drug: Codeine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine (75 or 100 mg)
Study: 1488756
Drug: Postremission therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postremission therapy without prednisolone (PSL)
Study: 1488756
Drug: Postremission therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postremission therapy with prednisolone (PSL)
Study: 30320574
Drug: Music listening
Normalized name: Listerine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music listening (ML)
Study: 25592742
Drug: Souvenaid™ (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Souvenaid™ (125 ml/day)
Study: 16357116
Drug: Org 25969
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 25969 0.5 mg kg(‐1)
Study: 16357116
Drug: Org 25969
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 25969 4.0 mg kg(‐1)
Study: 16357116
Drug: Org 25969
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 25969 (various doses)
Study: 16357116
Drug: Org 25969
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 25969 (2-4 mg kg(‐1))
Study: 12813331
Drug: Low-dose unfractionated
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose unfractionated heparin (UFH) 5,000 U every 8 hours
Study: 8941507
Drug: Coca chewing
Normalized name: ERYTHROXYLUM COCA LEAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coca chewing (15 g)
Study: 1685100
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg of vecuronium
Study: 1685100
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg of vecuronium
Study: 1685100
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg of vecuronium
Study: 1685100
Drug: 0.4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg/kg of vecuronium
Study: 6127039
Drug: QH 25
Normalized name: Quinine Hydrochloride 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: QH 25 (0.25, 0.75, and 2.25 mg orally)
Study: 6127039
Drug: Salbutamol (2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (2, 6, and 18 mg orally)
Study: 28124506
Drug: Metformin up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin up to 1,000 mg twice daily
Study: 30796338
Drug: Home-based aerobic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based aerobic exercise and resistance training (aerobic exercise thrice weekly and resistance training twice weekly for 12 weeks)
Study: 18318773
Drug: Udenafil 200
Normalized name: udenafil
DrugBank: Udenafil (DB06267)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Udenafil 200 mg
Study: 25759565
Drug: Concurrent administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent administration of Udenafil and Dapoxetine
Study: 17159457
Drug: Quetiapine monotherapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine monotherapy, 300 or 600 mg/day
Study: 15019892
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy at the time of hospital discharge
Study: 11260155
Drug: Salmeterol (SM)
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Salmeterol (SM) 50 microg, twice daily for 1 week
Study: 9731049
Drug: Rituximab 375
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab 375 mg/m2 (8 weekly infusions) - Arm A
Study: 9731049
Drug: Rituximab 500
Normalized name: riTUXimab 500 MG in 50 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab 500 mg/m2 (1 infusion followed by 7 weekly infusions) - Arm B
Study: 8162926
Drug: Naloxone (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.8 mg)
Study: 28797049
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (BICA) (0.3 g/kg)
Study: 28797049
Drug: Placebo (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (4 g NaCl)
Study: 19149890
Drug: Oral ferrous
Normalized name: ferrous fumarate Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ferrous sulphate (80 mg/day of elemental iron) for one month
Study: 12688516
Drug: Antioxidant supplements
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplements (two capsules per day for 4 weeks)
Study: 12688516
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two capsules per day for 4 weeks)
Study: 10428158
Drug: 24-day regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 24-day regimen of low-dose combined oral contraceptive (60 microg gestodene and 15 microg ethinyl estradiol)
Study: 10428158
Drug: 21-day regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 21-day regimen of low-dose combined oral contraceptive (60 microg gestodene and 15 microg ethinyl estradiol)
Study: 2654865
Drug: Steroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid treatment (higher initial doses: >= 125 mg of cortisone or >= 100 mg of hydrocortisone)
Study: 24034663
Drug: Nebivolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol (5 mg/d, titrated to 10-20 mg/d)
Study: 19705272
Drug: Pleasantly arousing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pleasantly arousing images (e.g., skydiving)
Study: 19705272
Drug: Unpleasantly arousing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unpleasantly arousing images (e.g., an aimed gun)
Study: 15211412
Drug: Subcutaneous ring
Normalized name: RING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous ring block with levobupivacaine
Study: 15211412
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl (2 microg/kg) and paracetamol (30 mg/kg)
Study: 8002621
Drug: Thrice-weekly injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice-weekly injection of Romurutide (3 times per week for 3 weeks)
Study: 8002621
Drug: Five times
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five times per week injection (5 times per week for 2 weeks)
Study: 8002621
Drug: Thrice-weekly injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice-weekly injection of Romurutide
Study: 21975200
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 1-year MRI lesion activity and relapses
Study: 16392974
Drug: Longest duration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longest duration of abstinence achieved during treatment
Study: 12580650
Drug: CHO-PRO beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO-PRO beverage (355 ml; approximately 0.8 g carbohydrate (CHO).kg(-1) body wt and approximately 0.2 g protein.kg(-1) body wt)
Study: 9049582
Drug: YM17E 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: YM17E 150 mg twice daily (b.d.)
Study: 9049582
Drug: YM17E 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: YM17E 300 mg twice daily (b.d.)
Study: 7819790
Drug: Hepatitis A
Normalized name: HEPATITIS A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis A vaccine (Havrix, SKF) - 1 injection at day 0, 1 at D15, booster at 6 months
Study: 7819790
Drug: Yellow fever
Normalized name: yellow fever live
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yellow fever vaccine - 1 injection at day 0
Study: 7819790
Drug: Both hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both hepatitis A and yellow fever vaccines
Study: 30208343
Drug: 12-week stepped
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week stepped collaborative care intervention (cognitive behavioral therapy, CBT)
Study: 26156512
Drug: Training with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training with protein supplement (n = 18)
Study: 26156512
Drug: Training with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training with placebo supplement (n = 13)